We have located links that may give you full text access.
Inhibition of miR‑34a prevents endothelial cell apoptosis by directly targeting HDAC1 in the setting of atherosclerosis.
Molecular Medicine Reports 2018 March
Despite recent medical advances, atherosclerosis is a global burden accounting for numerous mortalities and hospital admissions. MicroRNAs (miRNAs/miRs) regulate cardiovascular biology and disease, but the role of microRNA‑34a in atherosclerosis remains unclear. In the present study, it was demonstrated that miR‑34a was highly expressed in atherosclerotic lesions and oxidized low‑density lipoprotein (Ox‑LDL)‑treated human aortic endothelial cells (HAECs) (atherosclerotic cell model) using reverse transcription‑quantitative polymerase chain reaction. The expression of histone deacetylase (HDAC) 1 was reduced in atherosclerotic lesions and Ox‑LDL treated HAECs. TargetScan predicted that HDAC1 is the potential target of miR‑34a and the double‑luciferase reporter assay confirmed that HDAC1 was directly targeted by miR‑34a. Furthermore, miR‑34a inhibitor significantly enhanced the cell viability of HAECs and the cell apoptosis was suppressed. In addition, the expression of apoptotic‑related proteins was detected by western blotting. The results showed that miR‑34a inhibitor significantly upregulated B‑cell lymphoma 2, procaspase‑3, procaspase‑9 and proto‑oncogene c‑Myc protein expression, and downregulated the expression of p21. In contrast, co‑transfection of HDAC1‑small interfering RNA and miR‑34a inhibitor eliminated the effects of miR‑34a on HAECs. This indicated that miR‑34a inhibitor promoted cell viability and prevented cell apoptosis of HAECs through regulating HDAC1. In conclusion, it was demonstrated that miR‑34a promoted atherosclerotic formation by modulating the proliferation and apoptosis of HAECs, and regulating the expression of apoptosis‑related proteins by targeting HDAC1.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app